Compare McCormick & Company, Incorporated (MKC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novartis AG — how do they compare? McCormick & Company, Incorporated trades at $51.43 (market cap $13.96B), while Novartis AG trades at $138.16 (market cap $262.64B). The key difference: Novartis AG is far larger — about 18.8× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.7%). Which is the better fit depends on your goals.
| MKC | NVS | |
|---|---|---|
Market Cap | $13.96B | $262.64B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $168.62 |
52-Week Low | $45.60 | $121.80 |
Enterprise Value | $18.57B | $303.97B |
Dividend Yield | 3.7% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.64, net income margin of 21.91%, and consistent dividend growth. Recent Q1 2026 earnings beat expectations, while analyst consensus remains mixed with 11 buy, 17 hold, and 2 sell ratings. The pending $65 billion Unilever Foods merger and London listing plans represent significant corporate developments.
MKC presents a compelling value opportunity with attractive valuation metrics and stable profitability. The Unilever merger offers substantial growth potential but carries integration risks. Current technical weakness near support at $50-$51 creates a potential entry point for long-term investors seeking dividend income and merger upside.
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
